SYENS SYENSQO

Syensqo releases 2024 annual integrated report

Syensqo releases 2024 annual integrated report

Syensqo releases 2024 annual integrated report

Brussels, Belgium – March 28, 2025 - 08:30 CET

Syensqo has published its 2024 annual integrated report today giving its stakeholders a comprehensive and integrated overview of the company's strategy, business activities and performance for its first year. 

The report comprises the company’s financial and extra-financial statements, compliant with the EU Corporate Sustainability Reporting Directive (CSRD), One Planet roadmap progress on Climate, Nature, Growth, and Better Life.

The 2024 annual integrated report is posted in the of the . A European Single Electronic Format (ESEF) as required by EU Regulation 2019/815 is also available for download.

Contacts

Investors & Analysts

Media

Sherief Bakr

Bisser Alexandrov

Loïc Flament
9



0
Perrine Marchal

Laetitia Schreiber
2

7

About Syensqo 

Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates.

Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and health care applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Investor Relations sources

Attachments



EN
28/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYENSQO

 PRESS RELEASE

Syensqo - Acquisition of own shares

Syensqo - Acquisition of own shares Regulated Acquisition of own shares  Brussels, October 20, 2025 - 17:45 CET In accordance with article 7:215 of the Belgian Code of Companies and Associations, Syensqo SA (“Syensqo” or the “Company”) pursues its Share Buyback Program (or the “Program”) announced on September 30, 2024, covering up to €300 million. The fourth tranche began on July 31, 2025 and will cover a maximum amount of up to €50 million (of the €300 million Program). The Company intends to cancel all shares acquired through this tranche.  In the framework of this tran...

 PRESS RELEASE

Syensqo - Participation notification by Capital Group Companies Inc.

Syensqo - Participation notification by Capital Group Companies Inc. Regulated Participation notification by Capital Group Companies Inc. Brussels, Belgium – October 14, 2025 - 8:30 CEST According to Belgian transparency legislation (Law of May 2, 2007), The Capital Group Companies, Inc. (333 South Hope Street 55fl. Los Angeles, CA 90071) recently sent Syensqo the following transparency notifications indicating that it crossed the threshold of 3%. Here is the summary of the moves: Date on which the threshold was crossed Voting rights after the transaction Equival...

 PRESS RELEASE

Syensqo - Acquisition of own shares

Syensqo - Acquisition of own shares Regulated Acquisition of own shares  Brussels, October 13, 2025 - 17:45 CET In accordance with article 7:215 of the Belgian Code of Companies and Associations, Syensqo SA (“Syensqo” or the “Company”) pursues its Share Buyback Program (or the “Program”) announced on September 30, 2024, covering up to €300 million. The fourth tranche began on July 31, 2025 and will cover a maximum amount of up to €50 million (of the €300 million Program). The Company intends to cancel all shares acquired through this tranche.  In the framework of thi...

Guy Sips ... (+4)
  • Guy Sips
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASML: Chinese advanced DUV machine on trial; Azelis: Muddling through 2025 PostNL: CMD - new strategy and ambitions for 2028; Proximus: New CEO of Proximus Global announced Syensqo: CEO succession; UCB: Brivekimig (Sanofi) P2a results in Hidradenitis Suppurativa

ResearchPool Subscriptions

Get the most out of your insights

Get in touch